Proxalutamide clinical trials
Also written GT0918.
How each study uses proxalutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Suzhou Kintor Pharmaceutical Inc, (4) · Applied Biology, Inc. (1) · Hongqian Guo (1)
Studies
Open first, then newest update. How each study uses proxalutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPCCompletedPhase 2Suzhou Kintor Pharmaceutical Inc,NCT03899467Written as GT0918How we know
- A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 SubjectsTerminatedPhase 3Suzhou Kintor Pharmaceutical Inc,NCT05009732Written as GT0918How we know
- Anti-Androgen Treatment for COVID-19CompletedNot applicableApplied Biology, Inc.NCT04446429Written as ProxalutamideHow we know
- Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate CancerStatus unknownPhase 2Hongqian GuoNCT05076851Written as ProxalutamideHow we know
- Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast CancerCompletedPhase 1Suzhou Kintor Pharmaceutical Inc,NCT04103853Written as ProxalutamideHow we know
- Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate CancerCompletedPhase 1Suzhou Kintor Pharmaceutical Inc,NCT02826772Written as GT0918How we know
As the comparator · 5 — what is tested is compared with proxalutamide
- Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 IllnessCompletedPhase 3Suzhou Kintor Pharmaceutical Inc,NCT04870606Written as Proxalutamide (GT0918)How we know
- Proxalutamide Treatment for COVID-19 Patients in Intensive Care UnitWithdrawnPhase 3Applied Biology, Inc.NCT04853927Written as ProxalutamideHow we know
- Proxalutamide Treatment for COVID-19 Female OutpatientsWithdrawnPhase 3Applied Biology, Inc.NCT04853134Written as ProxalutamideHow we know
- The South Proxa-Rescue AndroCoV Trial Against COVID-19CompletedPhase 3Corpometria InstituteNCT05126628Written as ProxalutamideHow we know
- Proxalutamide Treatment for Hospitalized COVID-19 PatientsCompletedPhase 3Applied Biology, Inc.NCT04728802Written as ProxalutamideHow we know
Codes
What other systems call proxalutamide · ClinicalTrials.gg INT000276
- MeSH (NLM) C000599887proxalutamideOne source NLM
- UNII (FDA) QX6O64GP40PRUXELUTAMIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27287540proxalutamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C130036ProxalutamideOne source FDA
- DrugBank DB16065One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599887 | proxalutamide | One source NLM |
| UNII (FDA) | QX6O64GP40 | PRUXELUTAMIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27287540 | proxalutamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C130036 | Proxalutamide | One source FDA |
| DrugBank | DB16065 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.